Skip to main content
Top
Published in: Virology Journal 1/2023

Open Access 01-12-2023 | Research

Molecular epidemiology and clinical characteristics of enteroviruses associated HFMD in Chengdu, China, 2013–2022

Authors: Qiuxia Yang, Fang Liu, Li Chang, Shuyu Lai, Jie Teng, Jiaxin Duan, Hui Jian, Ting Liu, Guanglu Che

Published in: Virology Journal | Issue 1/2023

Login to get access

Abstract

Objectives

This study aims to investigate molecular epidemiology and clinical characteristics of enterovirus associated hand-foot-mouth disease (HFMD) in Chengdu, China, 2013–2022. Monitoring the molecular epidemiology and clinical features of HFMD for up to 10 years may provide some ideas for future protection and control measures.

Methods

We conducted a retrospective analysis of the medical records of all patients with laboratory-confirmed HFMD-related enterovirus infection at the West China Second University Hospital from January 2013 to December 2022. We described the characteristics in serotype, age, sex distribution and hospitalization of enterovirus infection cases using data analysis and graphic description.

Results

A total of 29,861 laboratory-confirmed cases of HFMD-related enterovirus infection were reported from 2013 to 2022. There was a significant reduction in the number and proportion of EV-A71 cases after 2016, from 1713 cases (13.60%) in 2013–2015 to 150 cases (1.83%) in 2017–2019. During the COVID-19 pandemic, EV-A71 cases even disappeared. The proportion of CV-A16 cases decreased from 13.96% in 2013–2015 to 10.84% in 2017–2019 and then to 4.54% in 2020–2022. Other (non-EV-A71 and non-CV-A16) serotypes accounted for 95.45% during 2020–2022, with CV-A6 accounting for 50.39% and CV-A10 accounting for 10.81%. Thus, CV-A6 and CV-A10 became the main prevalent serotypes. Furthermore, There was no significant difference in the enterovirus prevalence rate between males and females. The hospitalization rate of EV-A71 patients was higher that of other serotypes. In general, the proportion of HFMD hospitalizations caused by other pathogens except for EV-A71, CV-A16, CV-A10 and CV-A16 was second only to that caused by EV-A71. The proportion of children over 4 years old infected with enterovirus increased.

Conclusion

The incidence of HFMD associated with enterovirus infection has decreased significantly and CV-A6 has been the main pathogen of HFMD in Chengdu area in recent years. The potential for additional hospitalizations for other untested enterovirus serotypes suggested that attention should also be paid to the harms of infections with unknown enterovirus serotypes. Children with HFMD were older. The development of new diagnostic reagents and vaccines may play an important role in the prevention and control of enterovirus infection.
Appendix
Available only for authorised users
Literature
2.
go back to reference Li XW, Ni X, Qian SY, Wang Q, Jiang RM, Xu WB, Zhang YC, Yu GJ, Chen Q, Shang YX, Zhao CS, Yu H, Zhang T, Liu G, Deng HL, Gao J, Ran XG, Yang QZ, Xu BL, Huang XY, Wu XD, Bao YX, Chen YP, Chen ZH, Liu QQ, Lu GP, Liu CF, Wang RB, Zhang GL, Gu F, Xu HM, Li Y, Yang T. Chinese guidelines for the diagnosis and treatment of hand, foot and mouth disease (2018 edition). World J Pediatr. 2018;14:437–47.CrossRefPubMed Li XW, Ni X, Qian SY, Wang Q, Jiang RM, Xu WB, Zhang YC, Yu GJ, Chen Q, Shang YX, Zhao CS, Yu H, Zhang T, Liu G, Deng HL, Gao J, Ran XG, Yang QZ, Xu BL, Huang XY, Wu XD, Bao YX, Chen YP, Chen ZH, Liu QQ, Lu GP, Liu CF, Wang RB, Zhang GL, Gu F, Xu HM, Li Y, Yang T. Chinese guidelines for the diagnosis and treatment of hand, foot and mouth disease (2018 edition). World J Pediatr. 2018;14:437–47.CrossRefPubMed
3.
go back to reference Puenpa J, Wanlapakorn N, Vongpunsawad S, Poovorawan Y. The history of enterovirus A71 outbreaks and molecular epidemiology in the Asia-Pacific region. J Biomed Sci. 2019;26:75.CrossRefPubMedPubMedCentral Puenpa J, Wanlapakorn N, Vongpunsawad S, Poovorawan Y. The history of enterovirus A71 outbreaks and molecular epidemiology in the Asia-Pacific region. J Biomed Sci. 2019;26:75.CrossRefPubMedPubMedCentral
4.
go back to reference Yi Z, Pei S, Suo W, Wang X, Huang Z, Yi A, Wang B, He Z, Wang R, Li Y, Fan W, Huang X. Epidemiological characteristics, routine laboratory diagnosis, clinical signs and risk factors for hand, -foot -and -mouth disease: a systematic review and meta-analysis. PLoS ONE. 2022;17: e0267716.CrossRefPubMedPubMedCentral Yi Z, Pei S, Suo W, Wang X, Huang Z, Yi A, Wang B, He Z, Wang R, Li Y, Fan W, Huang X. Epidemiological characteristics, routine laboratory diagnosis, clinical signs and risk factors for hand, -foot -and -mouth disease: a systematic review and meta-analysis. PLoS ONE. 2022;17: e0267716.CrossRefPubMedPubMedCentral
5.
go back to reference Nassef C, Ziemer C, Morrell DS. Hand-foot-and-mouth disease: a new look at a classic viral rash. Curr Opin Pediatr. 2015;27:486–91.CrossRefPubMed Nassef C, Ziemer C, Morrell DS. Hand-foot-and-mouth disease: a new look at a classic viral rash. Curr Opin Pediatr. 2015;27:486–91.CrossRefPubMed
6.
go back to reference Mao QY, Wang Y, Bian L, Xu M, Liang Z. EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD). Expert Rev Vaccines. 2016;15:599–606.CrossRefPubMed Mao QY, Wang Y, Bian L, Xu M, Liang Z. EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD). Expert Rev Vaccines. 2016;15:599–606.CrossRefPubMed
7.
go back to reference Swain SK, Gadnayak A, Mohanty JN, Sarangi R, Das J. Does enterovirus 71 urge for effective vaccine control strategies? Challenges and current opinion. Rev Med Virol. 2022;32: e2322.CrossRefPubMed Swain SK, Gadnayak A, Mohanty JN, Sarangi R, Das J. Does enterovirus 71 urge for effective vaccine control strategies? Challenges and current opinion. Rev Med Virol. 2022;32: e2322.CrossRefPubMed
9.
go back to reference Esposito S, Principi N. Hand, foot and mouth disease: current knowledge on clinical manifestations, epidemiology, aetiology and prevention. Eur J Clin Microbiol Infect Dis. 2018;37:391–8.CrossRefPubMed Esposito S, Principi N. Hand, foot and mouth disease: current knowledge on clinical manifestations, epidemiology, aetiology and prevention. Eur J Clin Microbiol Infect Dis. 2018;37:391–8.CrossRefPubMed
10.
go back to reference Swain SK, Panda S, Sahu BP, Sarangi R. Activation of host cellular signaling and mechanism of enterovirus 71 viral proteins associated with hand Foot and Mouth Disease. Viruses. 2022;14(10):2190.CrossRefPubMedPubMedCentral Swain SK, Panda S, Sahu BP, Sarangi R. Activation of host cellular signaling and mechanism of enterovirus 71 viral proteins associated with hand Foot and Mouth Disease. Viruses. 2022;14(10):2190.CrossRefPubMedPubMedCentral
12.
go back to reference Song Y, Zhang Y, Han Z, Xu W, Xiao J, Wang X, Wang J, Yang J, Yu Q, Yu D, Chen J, Huang W, Li J, Xie T, Lu H, Ji T, Yang Q, Yan D, Zhu S, Xu W. Genetic recombination in fast-spreading coxsackievirus A6 variants: a potential role in evolution and pathogenicity. Virus Evol. 2020;6:veaa048.CrossRefPubMedPubMedCentral Song Y, Zhang Y, Han Z, Xu W, Xiao J, Wang X, Wang J, Yang J, Yu Q, Yu D, Chen J, Huang W, Li J, Xie T, Lu H, Ji T, Yang Q, Yan D, Zhu S, Xu W. Genetic recombination in fast-spreading coxsackievirus A6 variants: a potential role in evolution and pathogenicity. Virus Evol. 2020;6:veaa048.CrossRefPubMedPubMedCentral
13.
go back to reference Duan X, Zhang C, Wang X, Ren X, Peng H, Tang X, Zhang L, Chen Z, Ye Y, Zheng M, Zhong W, Chen X, Zeng Y, Yuan P, Long L. Molecular epidemiology and clinical features of hand, foot and mouth disease requiring hospitalization after the use of enterovirus A71 inactivated vaccine in chengdu, China, 2017–2022: a descriptive study, Emerg. Microbes Infect. 2022;11:2510–9.CrossRef Duan X, Zhang C, Wang X, Ren X, Peng H, Tang X, Zhang L, Chen Z, Ye Y, Zheng M, Zhong W, Chen X, Zeng Y, Yuan P, Long L. Molecular epidemiology and clinical features of hand, foot and mouth disease requiring hospitalization after the use of enterovirus A71 inactivated vaccine in chengdu, China, 2017–2022: a descriptive study, Emerg. Microbes Infect. 2022;11:2510–9.CrossRef
14.
go back to reference Tang XQ, Zhang LZ, Meng JT, Chen H, Cheng Y, Yuan P, Long L. Epidemiological characteristics of hand, foot, and mouth disease and the effect of EV71 vaccination in Chengdu from 2012 to 2020. Sichuan Da Xue Xue Bao Yi Xue Ban. 2022;53:1074–80.PubMed Tang XQ, Zhang LZ, Meng JT, Chen H, Cheng Y, Yuan P, Long L. Epidemiological characteristics of hand, foot, and mouth disease and the effect of EV71 vaccination in Chengdu from 2012 to 2020. Sichuan Da Xue Xue Bao Yi Xue Ban. 2022;53:1074–80.PubMed
15.
go back to reference Tong WB, Wu XQ, He M, Yang FJ, Jiang Y, Zhang G, Zeng PB. Epidemiological and etiological characteristics of hand, foot, and mouth disease before and after introducing enterovirus 71 vaccines in Sichuan, China: a 6-year retrospective study. Chin Med J. 2021;134:3017–9.CrossRefPubMedPubMedCentral Tong WB, Wu XQ, He M, Yang FJ, Jiang Y, Zhang G, Zeng PB. Epidemiological and etiological characteristics of hand, foot, and mouth disease before and after introducing enterovirus 71 vaccines in Sichuan, China: a 6-year retrospective study. Chin Med J. 2021;134:3017–9.CrossRefPubMedPubMedCentral
16.
go back to reference Han Y, Chen Z, Zheng K, Li X, Kong J, Duan X, Xiao X, Guo B, Luan R, Long L. Epidemiology of hand, foot, and mouth disease before and after the introduction of enterovirus 71 vaccines in Chengdu, China, 2009–2018. Pediatr Infect Dis J. 2020;39:969–78.CrossRefPubMed Han Y, Chen Z, Zheng K, Li X, Kong J, Duan X, Xiao X, Guo B, Luan R, Long L. Epidemiology of hand, foot, and mouth disease before and after the introduction of enterovirus 71 vaccines in Chengdu, China, 2009–2018. Pediatr Infect Dis J. 2020;39:969–78.CrossRefPubMed
17.
go back to reference Song S, Wang P, Li J, Nie X, Liu L, Liu S, Yin X, Lin A. The indirect impact of control measures in COVID-19 pandemic on the incidence of other infectious diseases in China. Public Health Pract. 2022;4: 100278.CrossRef Song S, Wang P, Li J, Nie X, Liu L, Liu S, Yin X, Lin A. The indirect impact of control measures in COVID-19 pandemic on the incidence of other infectious diseases in China. Public Health Pract. 2022;4: 100278.CrossRef
18.
go back to reference Muselli M, Cofini V, Mammarella L, Carmignani C, Fabiani L, Desideri G, Necozione S. The impact of COVID-19 pandemic on emergency services. Ann Ig. 2022;34:248–58.PubMed Muselli M, Cofini V, Mammarella L, Carmignani C, Fabiani L, Desideri G, Necozione S. The impact of COVID-19 pandemic on emergency services. Ann Ig. 2022;34:248–58.PubMed
20.
go back to reference Xiao J, Zhu Q, Yang F, Zeng S, Zhu Z, Gong D, Li Y, Zhang L, Li B, Zeng W, Li X, Rong Z, Hu J, He G, Sun J, Lu J, Liu T, Ma W, Sun L. The impact of enterovirus A71 vaccination program on hand, foot, and mouth disease in Guangdong, China: a longitudinal surveillance study. J Infect. 2022;85:428–35.CrossRefPubMed Xiao J, Zhu Q, Yang F, Zeng S, Zhu Z, Gong D, Li Y, Zhang L, Li B, Zeng W, Li X, Rong Z, Hu J, He G, Sun J, Lu J, Liu T, Ma W, Sun L. The impact of enterovirus A71 vaccination program on hand, foot, and mouth disease in Guangdong, China: a longitudinal surveillance study. J Infect. 2022;85:428–35.CrossRefPubMed
21.
go back to reference Li Y, Zhou Y, Cheng Y, Wu P, Zhou C, Cui P, Song C, Liang L, Wang F, Qiu Q, Guo C, Zeng M, Long L, Cowling BJ, Yu H. Effectiveness of EV-A71 vaccination in prevention of paediatric hand, foot, and mouth disease associated with EV-A71 virus infection requiring hospitalisation in Henan, China, 2017–18: a test-negative case-control study, Lancet Child Adolesc. Health. 2019;3:697–704. Li Y, Zhou Y, Cheng Y, Wu P, Zhou C, Cui P, Song C, Liang L, Wang F, Qiu Q, Guo C, Zeng M, Long L, Cowling BJ, Yu H. Effectiveness of EV-A71 vaccination in prevention of paediatric hand, foot, and mouth disease associated with EV-A71 virus infection requiring hospitalisation in Henan, China, 2017–18: a test-negative case-control study, Lancet Child Adolesc. Health. 2019;3:697–704.
22.
go back to reference Wu H, Xue M, Wu C, Lu Q, Ding Z, Wang X, Fu T, Yang K, Lin J. Trend of hand, foot, and mouth disease from 2010 to 2021 and estimation of the reduction in enterovirus 71 infection after vaccine use in Zhejiang Province, China. PLoS One. 2022;17: e0274421.CrossRefPubMedPubMedCentral Wu H, Xue M, Wu C, Lu Q, Ding Z, Wang X, Fu T, Yang K, Lin J. Trend of hand, foot, and mouth disease from 2010 to 2021 and estimation of the reduction in enterovirus 71 infection after vaccine use in Zhejiang Province, China. PLoS One. 2022;17: e0274421.CrossRefPubMedPubMedCentral
23.
24.
go back to reference Liyuan SU, Liangzhi Z, Yong YUE, Min HU, Zhimiao YU, Lin MA. Analysis of Prevention and Control Effect of EV71 Vaccine Against HFMD in Chengdu City. J Prevent Med Inf. 2020;36:531–8. Liyuan SU, Liangzhi Z, Yong YUE, Min HU, Zhimiao YU, Lin MA. Analysis of Prevention and Control Effect of EV71 Vaccine Against HFMD in Chengdu City. J Prevent Med Inf. 2020;36:531–8.
25.
go back to reference Wang J, Jiang L, Zhang C, He W, Tan Y, Ning C. The changes in the epidemiology of hand, foot, and mouth disease after the introduction of the EV-A71 vaccine. Vaccine. 2021;39:3319–23.CrossRefPubMed Wang J, Jiang L, Zhang C, He W, Tan Y, Ning C. The changes in the epidemiology of hand, foot, and mouth disease after the introduction of the EV-A71 vaccine. Vaccine. 2021;39:3319–23.CrossRefPubMed
26.
27.
go back to reference Hong J, Liu F, Qi H, Tu W, Ward MP, Ren M, Zhao Z, Su Q, Huang J, Chen X, Le J, Ren X, Hu Y, Cowling B, Li Z, Chang Z, Zhang Z. Changing epidemiology of hand, foot, and mouth disease in China, 2013–2019: a population-based study. Lancet Reg Health West Pac. 2022;20: 100370.CrossRefPubMedPubMedCentral Hong J, Liu F, Qi H, Tu W, Ward MP, Ren M, Zhao Z, Su Q, Huang J, Chen X, Le J, Ren X, Hu Y, Cowling B, Li Z, Chang Z, Zhang Z. Changing epidemiology of hand, foot, and mouth disease in China, 2013–2019: a population-based study. Lancet Reg Health West Pac. 2022;20: 100370.CrossRefPubMedPubMedCentral
Metadata
Title
Molecular epidemiology and clinical characteristics of enteroviruses associated HFMD in Chengdu, China, 2013–2022
Authors
Qiuxia Yang
Fang Liu
Li Chang
Shuyu Lai
Jie Teng
Jiaxin Duan
Hui Jian
Ting Liu
Guanglu Che
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2023
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-023-02169-x

Other articles of this Issue 1/2023

Virology Journal 1/2023 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.